Log in

NYSEAMERICAN:ARMP - Armata Pharmaceuticals Stock Price, Forecast & News

-0.32 (-7.19 %)
(As of 02/24/2020 04:35 AM ET)
Today's Range
Now: $4.13
50-Day Range N/A
52-Week Range
Now: $4.13
Volume66,160 shs
Average Volume367,720 shs
Market Capitalization$41.03 million
P/E RatioN/A
Dividend YieldN/A
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.

Industry, Sector and Symbol

Industry Biotechnology
SectorHealth Technology
Phone(310) 655-2928



Sales & Book Value

Annual SalesN/A



Market Cap$41.03 million
Next Earnings Date3/23/2020 (Estimated)
OptionableNot Optionable

Receive ARMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ARMP and its competitors with MarketBeat's FREE daily newsletter.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Frequently Asked Questions

What is Armata Pharmaceuticals' stock symbol?

Armata Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ARMP."

How were Armata Pharmaceuticals' earnings last quarter?

Armata Pharmaceuticals Inc (NYSEAMERICAN:ARMP) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.34. View Armata Pharmaceuticals' Earnings History.

When is Armata Pharmaceuticals' next earnings date?

Armata Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 23rd 2020. View Earnings Estimates for Armata Pharmaceuticals.

What price target have analysts set for ARMP?

3 Wall Street analysts have issued 12-month price objectives for Armata Pharmaceuticals' stock. Their forecasts range from $8.00 to $9.50. On average, they expect Armata Pharmaceuticals' share price to reach $8.83 in the next year. This suggests a possible upside of 113.9% from the stock's current price. View Analyst Price Targets for Armata Pharmaceuticals.

What is the consensus analysts' recommendation for Armata Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Armata Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Armata Pharmaceuticals.

What are Wall Street analysts saying about Armata Pharmaceuticals stock?

Here are some recent quotes from research analysts about Armata Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company's principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California. " (1/14/2020)
  • 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy and $7 price target. The sole contributor to our valuation, at this point is AB-SA01, with a projected 15% chance of success with $415 million in peak sales off of a 2024 launch. Overall, we believe that our projected chance of success could be considered conservative based on the efficacy and safety profile, to date, in very sick patients, and continues to highlight the valuation disconnect, in our belief. We do not include projections for the P. aeruginosa program, and would look to reevaluate based on visibility on the path forward." (8/15/2019)

Has Armata Pharmaceuticals been receiving favorable news coverage?

News stories about ARMP stock have been trending positive recently, InfoTrie reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Armata Pharmaceuticals earned a news impact score of 3.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Armata Pharmaceuticals.

Are investors shorting Armata Pharmaceuticals?

Armata Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totalling 154,100 shares, an increase of 36.7% from the January 15th total of 112,700 shares. Based on an average daily volume of 16,800 shares, the short-interest ratio is currently 9.2 days. Approximately 4.0% of the shares of the stock are sold short. View Armata Pharmaceuticals' Current Options Chain.

Who are some of Armata Pharmaceuticals' key competitors?

What other stocks do shareholders of Armata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Armata Pharmaceuticals investors own include Agile Therapeutics (AGRX), Vaxart (VXRT), Nabriva Therapeutics (NBRV), Aduro BioTech (ADRO), vTv Therapeutics (VTVT), Senseonics (SENS), VBI Vaccines (VBIV), Altimmune (ALT), OpGen (OPGN) and TrovaGene (TROV).

Who are Armata Pharmaceuticals' key executives?

Armata Pharmaceuticals' management team includes the folowing people:
  • Todd R. Patrick, Chief Executive Officer & Director
  • Brian C. Varnum, President & Chief Development Officer
  • Duane A. Morris, Vice President-Operations
  • Steven Robert Martin, Chief Financial Officer & Head-Media Contacts

Who are Armata Pharmaceuticals' major shareholders?

Armata Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Edgewood Management LLC (0.20%).

Which major investors are buying Armata Pharmaceuticals stock?

ARMP stock was acquired by a variety of institutional investors in the last quarter, including Edgewood Management LLC.

How do I buy shares of Armata Pharmaceuticals?

Shares of ARMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Armata Pharmaceuticals' stock price today?

One share of ARMP stock can currently be purchased for approximately $4.13.

How big of a company is Armata Pharmaceuticals?

Armata Pharmaceuticals has a market capitalization of $41.03 million. View Additional Information About Armata Pharmaceuticals.

How can I contact Armata Pharmaceuticals?

The company can be reached via phone at (310) 655-2928.

MarketBeat Community Rating for Armata Pharmaceuticals (NYSEAMERICAN ARMP)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  23 (Vote Outperform)
Underperform Votes:  18 (Vote Underperform)
Total Votes:  41
MarketBeat's community ratings are surveys of what our community members think about Armata Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Featured Article: Capital Gains Distribution

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel